X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (248) 248
humans (226) 226
bcr-abl1 (207) 207
hematology (169) 169
chronic myeloid leukemia (168) 168
chronic myelogenous leukemia (142) 142
oncology (137) 137
fusion proteins, bcr-abl - genetics (128) 128
imatinib (111) 111
leukemia, myelogenous, chronic, bcr-abl positive - genetics (110) 110
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (104) 104
leukemia (98) 98
male (88) 88
chronic myeloid-leukemia (86) 86
female (86) 86
middle aged (81) 81
hemic and lymphatic diseases (80) 80
adult (79) 79
tyrosine kinase inhibitors (77) 77
protein kinase inhibitors - therapeutic use (70) 70
imatinib mesylate (65) 65
aged (64) 64
cml (64) 64
tyrosine (63) 63
antineoplastic agents - therapeutic use (56) 56
bcr-abl (56) 56
analysis (52) 52
bcr‐abl1 (51) 51
dasatinib (51) 51
prognosis (51) 51
cancer (49) 49
philadelphia chromosome (49) 49
genetic aspects (47) 47
treatment outcome (47) 47
follow-up (46) 46
minimal residual disease (45) 45
mutation (43) 43
tyrosine kinase inhibitor (41) 41
adolescent (40) 40
pyrimidines - therapeutic use (40) 40
young adult (40) 40
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (39) 39
nilotinib (39) 39
chronic myeloid leukaemia (38) 38
research (36) 36
care and treatment (35) 35
therapy (35) 35
bcr-abl1 transcript levels (34) 34
leukemia, myelogenous, chronic, bcr-abl positive - pathology (34) 34
hematology, oncology and palliative medicine (32) 32
patients (32) 32
polymerase-chain-reaction (32) 32
myeloid leukemia (31) 31
piperazines - therapeutic use (31) 31
fusion proteins, bcr-abl - metabolism (30) 30
philadelphia-chromosome (30) 30
polymerase chain reaction (30) 30
protein-tyrosine kinase (30) 30
recommendations (30) 30
aged, 80 and over (29) 29
chronic-phase (29) 29
kinases (29) 29
early molecular response (27) 27
stem cells (26) 26
acute lymphoblastic-leukemia (25) 25
medicine & public health (25) 25
molecular response (24) 24
pathology (24) 24
resistance (24) 24
antineoplastic agents (23) 23
chromosomes (23) 23
leukemia, myelogenous, chronic, bcr-abl positive - mortality (23) 23
stem-cells (23) 23
benzamides (22) 22
diagnosis (22) 22
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (22) 22
bcr-abl transcripts (21) 21
imatinib mesylate - therapeutic use (21) 21
precursor cell lymphoblastic leukemia-lymphoma - genetics (21) 21
antimitotic agents (20) 20
cml patients (20) 20
drug resistance, neoplasm (20) 20
drug resistance, neoplasm - genetics (20) 20
survival (20) 20
tyrosine kinase (20) 20
acute lymphocytic leukemia (19) 19
chemotherapy (19) 19
diagnosed chronic-phase (19) 19
gene expression (19) 19
rna, messenger - genetics (19) 19
bcr/abl1 (18) 18
bone marrow (18) 18
child (18) 18
drug therapy (18) 18
european leukemianet (18) 18
genes (18) 18
protein-tyrosine kinases - antagonists & inhibitors (18) 18
acute lymphoblastic leukemia (17) 17
cytogenetic response (17) 17
disease-free survival (17) 17
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Virchows Archiv, ISSN 0945-6317, 9/2015, Volume 467, Issue 3, pp. 357 - 363
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2008, Volume 143, Issue 4, pp. 503 - 510
Journal Article
International Journal of Laboratory Hematology, ISSN 1751-5521, 02/2019, Volume 41, Issue 1, pp. 46 - 54
Journal Article
ANTICANCER RESEARCH, ISSN 0250-7005, 07/2019, Volume 39, Issue 7, pp. 3949 - 3954
We report the case of an 89-year-old male diagnosed with chronic-phase CML and expressing a rare e13a3 BCR-ABL1 fusion transcript. His cytogenetic analysis... 
CML | BCR/ABL | IMATINIB TREATMENT | CHRONIC MYELOID-LEUKEMIA | dasatinib | BCR-ABL FUSION | GENE | ONCOLOGY | BCR-ABL1 | ACUTE LYMPHOBLASTIC-LEUKEMIA | OUTCOMES | PCR | e13a3 | Translocation | BCR protein | Hematology | Transcription | Leukemia | Philadelphia chromosome | Polymerase chain reaction | Primers | Cytogenetics | Catalysis | Mutation | Chromosomes | Elderly | Geriatrics
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 10/2019, Volume 60, Issue 12, pp. 3051 - 3057
The prognostic significance of rare BCR-ABL1 transcripts is uncertain in the tyrosine kinase inhibitor (TKI) era. In this retrospective study, 40 (1.7%)... 
rare BCR-ABL1 transcripts | Chronic myeloid leukemia | tyrosine kinase inhibitor | prognosis | cytogenetic response
Journal Article
European Journal of Haematology, ISSN 0902-4441, 07/2019, Volume 103, Issue 1, pp. 26 - 34
Journal Article
Oncology letters, ISSN 1792-1074, 09/2019, Volume 18, Issue 3, pp. 2648 - 2653
We report a case of chronic myeloid leukemia in a 52-year-old male expressing a rare e14a3 fusion transcript. Cytogenetic analysis showed the t(9;22)... 
BCR-ABL FUSION | GENE | ONCOLOGY | nilotinib | BCR-ABL1 | ACUTE LYMPHOBLASTIC-LEUKEMIA | IMATINIB | chronic myeloid leukemia | case report | e14a3 | PCR | CHRONIC MYELOID-LEUKEMIA
Journal Article
REVISTA DE CHIMIE, ISSN 0034-7752, 09/2019, Volume 70, Issue 9, pp. 3193 - 3196
Chronic myeloid leukemia (CML) is a chronic myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome. Oxidative stress is... 
tyrosine kinase inhibitors | ENGINEERING, CHEMICAL | STEM-CELLS | INSTABILITY | PATHWAY | ANTIOXIDANT STATUS | IMATINIB | BCR-ABL1 transcript | CONTRIBUTES | CHEMISTRY, MULTIDISCIPLINARY | oxidative stress | chronic myeloid leukaemia
Journal Article
Journal Article
Journal Article